MCOLN1 and Alzheimer disease: Together, these results highlight key defects in the TRPML1 endolysosomal system in AD pathogenesis and point to TRPML1 as a novel therapeutic target to remediate EAL neuropathogenesis in AD and related neurodegenerative disease.